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Abstract 1 
 2 
Follicle-stimulating hormone (FSH) is synthesized in the pituitary by gonadotrope 3 
cells. By binding to and interacting with its cognate receptor (FSHR) in the gonads, this 4 
gonadotropin plays a key role in the control of gonadal function and reproduction. Upon 5 
activation, the FSHR undergoes conformational changes leading to transduction of 6 
intracellular signals, including dissociation of G protein complexes into components and 7 
activation of several associated interacting partners, which concertedly regulate 8 
downstream effectors. The canonical Gs/cAMP/protein kinase A pathway, considered for 9 
a long time as the sole effector of FSHR-mediated signaling, is now viewed as one of 10 
several mechanisms employed by this receptor to transduce intracellular signals in 11 
response to the FSH stimulus. This complex network of signaling pathways allows for a 12 
fine-tuning regulation of the gonadotropic stimulus, where activation/inhibition of its 13 
multiple components vary depending on the cell context, cell developmental stage, and 14 
concentration of associated receptors and corresponding ligands. Activation of these 15 
multiple signaling modules eventually converge to the hormone-integrated biological 16 
response, including survival, proliferation and differentiation of target cells, synthesis and 17 
secretion of paracrine/autocrine regulators and, at the molecular level, functional 18 
selectivity and differential gene expression.  19 
 20 
In this minireview, we briefly discuss the complexity of FSHR-mediated intracellular 21 
signals activated in response to ligand stimulation. A better understanding of the signaling 22 
pathways involved in FSH action might potentially influence the development of new 23 
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therapeutic strategies for reproductive disorders. 24 
 25 
Words: 228 26 
 27 
Abbreviations:  28 
 29 
APPL, adaptor protein containing pleckstrin homology domain, phosphotyrosine binding 30 
domain, and leucine zipper motif; AREG, amphiregulin or aregulin;  CREB, cAMP-31 
response element binding protein; EGFR, epidermal growth factor receptor; EPAC, 32 
exchange protein directly activated by cAMP; FOXO1a, forkhead box transcription factor 33 
O or forkhead homologue in rhabdomyosarcoma; GPCR, G protein-coupled receptor; 34 
IGF-1R, insulin-like growth factor 1 receptor; IP3, inositol 1,4,5 triphosphate;  mTOR, 35 
mammalian target of rapamycin; LHCGR, luteinizing hormone-chorionic gonadotropic 36 
hormone receptor; P70S6K, P70 S6 kinase; PI3K, phosphatidylinositol-3-kinase; PTEN, 37 
phosphatase and tensin homolog deleted in chromosome 10; rpS6, ribosomal protein S6; 38 
SFK, Src family of protein tyrosine kinases; Sgk, serum- and glucocorticoid-induced 39 
kinase; Src, Rous sarcoma oncogene. 40 
 41 
 42 
 43 
 44 
 45 
  46 
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Introduction 47 
 48 
 49 
Follicle-stimulating hormone or follitropin is synthesized in the anterior pituitary 50 
gland by gonadotrope cells. By binding to its cognate receptor in the female and male 51 
gonads, this gonadotropin plays a central role in the control of gonadal function and 52 
reproduction (1,2). The follicle-stimulating hormone receptor (FSHR) belongs to the highly 53 
conserved subfamily of the GPCR superfamily, the so-called Rhodopsin family and, more 54 
specifically, to the d-group of this large class of GPCRs (3). As other structurally related 55 
glycoprotein hormone receptors [the LHCGR and the TSH receptor (TSHR)], the FSHR 56 
is composed of a large NH2-terminal extracellular domain (ECD), where recognition and 57 
binding of its cognate ligand occur. The ECD is structurally linked by the so-called hinge 58 
region to the transmembrane domain (TMD), which is composed of seven a-helices 59 
connected by alternating intracellular and extracellular loops, and that is involved in the 60 
activation and signaling functionality of the receptor. The FSHR ends with a COOH-61 
terminus (or C-tail) at the intracellular side, which contains important functional motifs of 62 
the receptor (Fig. 1).  63 
 64 
The FSHR is primarily expressed by the gonads (5). In the testis, this receptor is 65 
located at the basolateral Sertoli cell surface, where it supports cell growth and 66 
maturation, and thereby spermatogenesis (8); in the ovary, the FSHR is expressed in the 67 
granulosa cells where FSH stimulation regulates growth and maturation of ovarian 68 
follicles and estrogen production (1). For many years the FSHR was thought to be 69 
localized exclusively in the gonads; nevertheless, new evidence from studies in 70 
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experimental animals and in humans have suggested that this receptor may also be 71 
present in extragonadal tissues where FSH may have distinct physiological roles (9). 72 
Nonetheless, some of these extragonadal tissues as targets for FSH action have been 73 
recently questioned (10), indicating that further studies are still required to validate the 74 
existence of extragonadally-expressed FSHRs.  75 
 76 
Studies on other GPCRs as well as on the FSHR, have shed some light on the 77 
mechanisms that presumably lead to FSHR activation and signal transduction. It appears 78 
that FSH primarily binds to the large ECD and that extracellular loops 1 and 3, which are 79 
extracellular projections of the TMD, represent potential secondary gonadotropin binding 80 
sites (11). Upon FSH binding, the transmembrane helices (particularly the TMD helices 81 
5, 6, 3, and 7) present a series of conformational changes and rearrangements that are 82 
transmitted down the intracellular extensions of the a-helices and associated intracellular 83 
domains (loops and C-tail; Fig. 1). This reorganization in intracellular domains in turn 84 
allows accommodation and activation of a number of effectors, including several receptor-85 
coupled G proteins and other associated proteins and interacting partners, triggering the 86 
activation of a number of downstream signaling cascades that will eventually lead to a 87 
biological effect. An interesting nuance of this and other GPCRs is that the a-helices 88 
conforming the TMD may oscillate between multiple conformations, that will define 89 
activation of several or distinct signaling pathways and account for biased signaling (5,12-90 
14). These multiple mechanisms explain the recruitment of manifold signaling molecules 91 
to the complex signaling network activated by the FSHR during follicular and Sertoli cell 92 
maturation. 93 
 94 
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In this review, we provide a brief overview of the multifaceted aspects of FSHR 95 
transduction, signaling and biological actions. 96 
 97 
Signal transduction at the FSHR: signaling pathways, interacting partners, and 98 
networks. 99 
  100 
Most investigators agree that the effects of gonadotropins on the differentiated 101 
function of their target cells are mainly mediated by the activation of the canonical 102 
Gs/adenylyl cyclase/cAMP/PKA pathway, which subsequently leads to CREB 103 
phosphorylation and modulation of gene transcription (5,15-20). Nevertheless, it is now 104 
clear that this particular signaling cascade is not the only one activated by the action of 105 
these hormones. As detailed below, gonadotropins activate additional pathways that are 106 
involved in several cellular processes as proliferation and/or differentiation and, at the 107 
molecular level, functional selectivity and differential gene expression (1,5,13,14,21-24). 108 
 109 
The FSHR is connected via conformational selectivity to a nonlinear and complex 110 
signaling network. This network can involve either several G protein subtypes, including 111 
the Gs, Gi, and Gq/11 proteins  (25-30), interaction with other receptors [e.g. the IGF-1R 112 
and the EGFR (24,31-33)] and proteins [e.g. b-arrestins, APPL1, FOXO1a, and 14-3-3t] 113 
(34-39), or heterodimerization with the LHCGR (26,40-42). These mechanisms have 114 
been reported to regulate a number of intertwined signaling pathways, including 115 
engagement of distinct kinases (such as PKA, PKC, PI3K, PKB/Akt, p70S6K and ERK1/2) 116 
(1,5,14,22,24,27,43,44) (Fig. 2). This complex signaling network allows for a fine-tuning 117 
regulation of the gonadotropic stimulus, where activation/inhibition of its multiple 118 
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components will vary depending on the cell context, developmental stage of the host cells, 119 
and concentration of receptors and ligands (1,9,24,43,46-48). Furthermore, preferential 120 
activation of distinct signaling modules by the FSHR occurring through stabilization of 121 
distinct FSHR conformations in response to binding of particular ligands or receptor 122 
mutations may also occur (Figs. 1 and 3) (14,49,50), paving the way for designing drug 123 
candidates that may elicit selective signaling at the gonadal level (51,52). Let us briefly 124 
dissect the complex signaling network turned on by the activated FSHR. 125 
 126 
Signaling through G proteins 127 
 128 
As mentioned previously, FSH binding triggers a sequence of conformational 129 
changes within the receptor, which promotes activation of intracellular signaling 130 
pathways.  The primary transduction effectors described for the FSHR are heterotrimeric 131 
G proteins (15,53,54). Upon Gs interaction with intracellular loops 2 and 3 of hormone-132 
bound FSHR on the ERW and BBXXB (B: basic residue and X: non-basic residue) motifs 133 
(Fig. 1) (19), adenylate cyclase is stimulated and cAMP-dependent intracellular targets 134 
are activated. One main target of cAMP is protein kinase A (PKA) that mediates FSH-135 
dependent signaling including the ERK MAPK cascade that controls Sertoli cell mitotic 136 
phase (43). In preantral granulosa cells, FSH-dependent activation of ERK is mediated 137 
through PKA-dependent destabilization of a constitutive 100 kDa MEK phospho-tyrosine 138 
phosphatase (55), identified recently as dual specificity phosphatase 6 or DUSP6 (56). In 139 
fact, activation of phosphatases by PKA appears to be a general mechanism whereby 140 
FSH stimulates components not only of MAPK cascades, but also of PI3K-dependent 141 
signaling, by indirectly enabling IGF-1R-transduced insulin receptor substrate 1 142 
phosphorylation in granulosa cells (57). In these cells, FSH-dependent PKA activation 143 
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also stimulates p38 MAPK, likely involved in Sgk activation (22) and in modeling 144 
granulosa cell shape (58). However, the relationship between FSH/PKA and p38 MAPK 145 
phosphorylation has been recently questioned by studies in which expression of a 146 
constitutively active form of PKA in granulosa cells was not sufficient alone to activate this 147 
particular pathway (59). 148 
  149 
 150 
 Protein kinase A is considered as the master regulator of transcription factors of 151 
the cAMP response element-binding protein (CREB)/activating transcription factors (ATF) 152 
family (60) (Fig. 2). Nonetheless, in FSH-stimulated Sertoli cells, PKA regulates the 153 
activity of other nuclear targets, such as the retinoic acid receptor α (61), an important 154 
modulator of male germ cell development. More generally, PKA activity could be involved 155 
in global chromatin remodeling, as illustrated by H3 histone phosphorylation in FSH-156 
stimulated granulosa cells (62). Noteworthy, the requirement of CREB itself on FSH-157 
dependent transcriptome also needs to be reconsidered because genome-wide 158 
sequencing technologies combined with bioinformatics analyses have recently underlined 159 
that FSH-responsive genes in human granulosa cells are notably enriched in binding 160 
motifs for GATA family of transcription factors, whereas the frequency of CREB-161 
dependent genes is much scarcer than initially anticipated (63). Scrutinizing FSH-162 
regulated promoter regions at the systems level will certainly bring to light the involvement 163 
of unexpected transcriptional regulators and upstream kinases in the future. 164 
 165 
 In addition to PKA, FSH-stimulated cAMP rise also activates the exchange proteins 166 
directly activated by cAMP or EPACs, that enhance small RAS-like GTPase Rap1 activity 167 
(24). EPAC is presumably involved in the activation of PKB/Akt (22), a PI3K target whose 168 
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activity is counteracted by PTEN to cease Sertoli cell proliferation (64). Likewise, in 169 
granulosa cells, Akt neutralizes the anti-proliferative effect of AMP-activated protein 170 
kinase (AMPK) (65,66) and promotes the phosphorylation and nuclear exclusion of 171 
FOXO1a, one of its prominent substrate that also hampers the G1/S phase transition. 172 
Interestingly, recent work has revealed that FOXO1a controls the expression of most 173 
FSH-responsive genes in these cells (67). Many of these genes correspond to those 174 
involved in autophagy (67,68), and recent studies suggest that FSH might protect 175 
granulosa cells from atresia in part by preventing mitophagy (69). The mechanisms 176 
involved encompass FOXO1a nuclear exclusion via PI3K/Akt/mTOR activation and 177 
inhibition of E3 Ubiquitin ligase Parkin recruitment in the outer membrane of damaged 178 
mithochondria by PTEN-induced putative kinase 1 (PINK1) (69). Not only Gs- but also β-179 
arrestin-dependent signaling might transduce the anti-atretic protective effect of FSH, as 180 
shown recently in granulosa cells (70). 181 
   182 
Both PKA and Akt-dependent pathways cooperatively interact to stimulate the 183 
mTOR and p70S6 kinase, ultimately leading to mRNA translation (48,71,72) (73)(Fig. 2). 184 
Translational regulation of mRNA in response to FSH has been proposed initially in 185 
granulosa cells (71,74). During granulosa cell proliferation, hormone-bound FSHR leads 186 
to Gs-dependent and ERK-mediated phosphorylation of TSC2 (tuberin), a mTOR effector 187 
that stimulates p70S6K activity, ultimately leading to enhanced cyclin D2 expression 188 
(74,75). Via the PI3K/Akt mTOR pathway, FSH stimulates the expression of hypoxia-189 
inducible factor-1 (HIF-1) mRNA, encoding a transcription factor that regulates the 190 
expression of vascular endothelial growth factor (VEGF) (71). Furthermore, activation of 191 
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FSH-mediated mTOR pathway also induces the expression of some follicular 192 
differentiation markers, such as the LHCGR, inhibin-α, P450AROM, or the βII-subunit of 193 
PKA. In the testis, cAMP- and PI3K/mTOR-dependent pathways also cooperate in the 194 
activation of p70S6K by inducing phosphorylation profiles that differ according to the 195 
development stage of Sertoli cells (48,72,73). This developmentally regulated 196 
phosphorylation profile of p70S6K is supported by the observation that during the Sertoli 197 
cell differentiation phase, Akt is phosphorylated directly by FSHR signaling and not via 198 
transactivation of the IGF-1R as shown in the mitotic phase (75,76), suggesting different 199 
properties of the PI3K-regulated network at both stages (48,72,73). By using these PI3K-200 
dependent signaling mechanisms, FSH may promote rearrangements and post-201 
translational modifications of initiation and elongation factors that form the translational 202 
machinery at the 5′ untranslated region (UTR) of mRNAs. For example, in Sertoli cells 203 
FSH stimulates the phosphorylation of eukaryotic translation initiation factor 4 (eIF4) G 204 
and eIF4B, a cofactor of the eIF4A RNA helicase, via mTOR and p70S6K respectively. 205 
In only a few minutes, all these molecular events induce cap-dependent translation of 206 
mRNAs such as VEGF and c-fos (72), as well as Internal Ribosome Entry Site (IRES)-207 
dependent mRNA translation (77). Cell responsiveness to FSH is not limited to the 208 
regulation of mRNA transcription and translation, and recent data have proposed that a 209 
complex miRNA network orchestrates the stability, and hence the dynamics, of various 210 
components of the FSH signaling network (78,79). For example, the stabilization of PTEN 211 
would occur through hormone-induced degradation of miRNAs complementary to the 212 
PTEN mRNA (80). PTEN is required for Sertoli cells to achieve terminal differentiation 213 
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(64) and its mRNA is spatially restricted at spermiation in the adluminal region of Sertoli 214 
cells (80).  215 
  216 
Like many other GPCRs, the FSHR receptor exhibits some tendency to 217 
promiscuity with other G proteins. For example, the FSHR has been reported to interact 218 
with Gi when activated by particular glycosylated variants of FSH (25,81,82). Likewise, in 219 
Sertoli cells at early stages of maturation, cyclin-D1 expression depends in part on Gi 220 
FSHR coupling (43). Further studies are needed to determine whether the FSHR variant 221 
expressed at this stage matches with the alternative splicing product of the FSHR 222 
identified previously in granulosa cells that stimulates Pertussis toxin-sensitive ERK 223 
phosphorylation but is unable to enhance cAMP levels (82). An analogous phenomenon 224 
of signaling dichotomy has been observed in cultured rat granulosa cells when the FSHR 225 
is occupied simultaneously by FSH and FSHR negative allosteric modulators, which 226 
promote persistent FSH-stimulated estradiol biosynthesis in the face of inhibited cAMP 227 
production (51). Besides, at supraphysiologic concentrations (>200 ng/ml), FSH also 228 
mediates FSHR coupling to Gq/11 (29,83) leading to increased IP3 levels.  229 
   230 
Role of FSHR associated partners, b-arrestins, Ca2+ mobilization, and cross-talk 231 
with other plasma membrane receptors in FSHR signaling 232 
 233 
APPL1, FOXO1a, and 14-3-3t. In addition to signaling through G proteins, the FSHR also 234 
directly interacts with a number of partners that elicit particular signaling mechanisms. 235 
These partners include, among others, the APPL1 adapter, the above-mentioned 236 
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FOXO1a, and 14-3-3t (34,35,37,38,84-86). The APPL1 adapter is an important regulator 237 
of signaling and trafficking events within cells, and is expressed in many tissues, including 238 
the testis and the ovary (87). In fact, this adapter interacts with many signaling proteins 239 
in a cell type-dependent manner. APPL1 may govern signal specificity and trafficking by 240 
interacting with PI3K and Akt (88) that in turn phosphorylates FOXO1a, as well as with 241 
the small GTPase Rab5 (89), a mediator of fusion of clathrin-coated vesicles with early 242 
endosomes (90). Studies employing a yeast interaction trap, identified APPL1 as an 243 
important interacting protein with the FSHR (35,37,38); furthermore, it has been found 244 
that linking between this adapter and the FSHR occurs at the intracellular loop (IL) IL1, 245 
specifically at Lys393, Leu394 and Phe399 (39) (Fig. 1). In HEK293 cells stably 246 
expressing the FSHR, APPL1 and 2 appear to be associated with each other via the NH2-247 
terminus of APPL1 in a FSH-independent manner (35,37,38). Given that the FSHR 248 
associates with APPL1 and interacts with FOXO1a (which does not interact with APPL1 249 
or 2) (38,66) and that APPL1 interacts with Akt (37), it has been proposed that the 250 
interplay between a FSHR-FOXO1a complex with an activated FSHR-APPL1-Akt 251 
complex leads to FOXO1a phosphorylation and abrogation of apoptosis (23,35). In fact, 252 
as described above, FSH stimulation results in rapid FOXO1a phosphorylation and its 253 
exclusion from the nucleus in granulosa cells (66). In the same vein, association of the 254 
FSHR with 14-3-3t has been mapped to the IL2, overlapping with the canonical G protein 255 
binding sites, specifically the ERW motif (Fig. 1) (35). 14-3-3 proteins are involved in a 256 
number of biological processes and play an important role in regulating signaling 257 
pathways by interacting with phosphorylated signaling proteins (91). In HEK293 cells, 258 
overexpression of 14-3-3t led to decreased cAMP levels (34) suggesting a role of 14-3-259 
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3t in FSHR/Gs-mediated signal transduction. The association of APPL1, 14-3-3t, and 260 
FOXO1a with the FSHR suggests that FSH causes phosphorylated FOXO1a to be 261 
sequestered to the cytosol by 14-3-3t, with APPL1 facilitating this process.  262 
 263 
b-arrestins. Besides evoking ERK1/2 phosphorylation through the Gs pathway, FSHR 264 
activates this particular signaling cascade through b-arrestins (43,85), which in addition 265 
to their well-recognized role in GPCR desensitization, internalization, and recycling (see 266 
below), have also emerged as important players in the regulation of GPCR signaling 267 
(13,86). The FSHR has been reported to be phosphorylated by PKA and PKC second 268 
messenger-dependent kinases but also by G protein-coupled receptor kinases (GRK) 2, 269 
3, 5, and 6 in various cell culture models (36,85,92-95). β-arrestins recruited to GRK2- or 270 
GRK5/6-phosphorylated FSHR have been shown to exert distinct intracellular functions 271 
in time and space: β-arrestin 1 and 2 binding to GRK2-phosphorylated FSHR leads to the 272 
internalization and recycling of the receptor, whereas phosphorylation of the FSHR by 273 
GRK5 and 6 is required for β-arrestin-dependent, heterotrimeric G protein-independent 274 
ERK signaling, as shown by other GPCRs  (13,85,96-99). Concurrently, these findings 275 
are consistent with a model of phosphorylation bar code elicited by distinct GRKs that 276 
could control the conformation of β-arrestin recruited to the receptor and thereby its ability 277 
to interact with specific partners (12,96-100). A well-documented illustration is the 278 
temporal encoding of ERK activation: in contrast to G protein-mediated ERK activation, 279 
which is rapid and transient, ERK recruitment and signaling activated by β-arrestins is 280 
slower (~5-10 min to reach maximum), but protracted (t1/2 >1 hour) (85). It has recently 281 
been demonstrated that the 5-hydroxytryptamine 2 receptor, β2-adrenergic receptor, 282 
CXC-chemokine receptor 4, and the FSHR activate the ERK pathway via a mechanism 283 
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involving MEK-dependent β-arrestin 2 phosphorylation at Thr383. Importantly, this 284 
agonist-induced phosphorylation of b-arrestin 2 is a necessary step for ERK recruitment 285 
to β-arrestin complex and for ERK activation (101). More recently, Gs-dependent and β-286 
arrestin-dependent FSH signaling have been shown to cooperatively activate p70S6K, 287 
within a constitutively assembled β-arrestin/p70S6K/rpS6 module (72,102,103); this 288 
complex controls the translation of 5′ TOP mRNAs, a subset of mRNAs representing 289 
almost 20% of cellular mRNA abundance and that encode for ribosomal proteins, poly(A)-290 
binding protein, and factors of the translational machinery (102-104). The co-joined action 291 
of Gs- and β-arrestin-transduced signaling on p70S6K contrasts with the parallel action 292 
that both effectors have on the ERK MAPK, whose kinetics of phosphorylation differs 293 
depending on the transducer (Gs vs β-arrestins)(50,85,103). Finally, the β-arrestin-294 
dependent intracellular signaling may be preferentially activated when the FSHR is 295 
stabilized in distinct conformation(s) in response to particular ligands or receptor 296 
mutations, in a process known as biased agonism or functional selectivity (Fig. 3), which 297 
is discussed below.  298 
 299 
Ca2+ mobilization. FSH-stimulated Ca2+ mobilization in both granulosa and Sertoli cells 300 
has been well recognized for a long time and it has been attributed to both rapid influx of 301 
Ca2+ through T-type Ca2+ channels as well as release from intracellular stores (28,30,105-302 
109), where Gi/Gbg/PI3K or Gs- and/or Gq-mediated activation of phospholipase C 303 
(PLC)b or other PLC isoforms appear to play an important role. In fact, in rat Sertoli cells, 304 
FSHR can signal through the transglutaminase Gah to promote extracellular Ca2+ 305 
mobilization by interacting with PLCd-1 (28). Moreover, studies in human granulosa cells 306 
revealed that in addition to the regulatory roles of APPL1 described above, interaction of 307 
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this adapter with the FSHR also leads to IP3 production and release of Ca2+ from 308 
intracellular stores (39). On the other hand, it has been shown that exposure of swine 309 
granulosa cells or rat Sertoli cells to FSH leads to a rapid increase in intracellular Ca2+ 310 
accumulation, which may occur in a cAMP-dependent (e.g. via stimulation of PLCe) and 311 
-independent (e.g. via the Gq/11 bg complex) manner (26,30,106,107,110,111). 312 
Whatever the mechanism(s) involved in Ca2+ mobilization, it seems that Ca2+-mediated 313 
signaling is important for FSH-regulated functional differentiation of granulosa and Sertoli 314 
cells (112-114).  315 
 316 
 317 
Cross-talk with other plasma membrane receptors in FSHR signaling. Among the 318 
mechanisms contributing to GPCR signal pleiotropy is receptor cross-talk, which may 319 
occur either via intracellular effectors or through heterodimerization. In this regard, the 320 
tyrosine kinase receptors IGF-1R and EGFR have emerged as important functional 321 
partners of the FSHR. Regarding the former, it has been shown that ligand-activated IGF-322 
1R and FSHR act synergistically to enhance steroidogenesis, LHCGR and inhibin-a 323 
expression, and cell proliferation in different cell contexts and species, albeit with some 324 
differences (33,115,116). In addition, both FSH and locally produced IGF-1 are essential 325 
for granulosa cells differentiation, follicle survival and fertility (33,117). Signaling mediated 326 
by both receptors converge and overlap in activating distinct signaling cascades 327 
downstream of adenylyl cyclase, mainly the PI3K/Akt pathway (22,31). Furthermore, 328 
female mice with conditional knockdown of the IGF-1R in granulosa cells or exposed to 329 
IGF-1R inhibitor, exhibited defective FSH-stimulated Akt activation and steroidogenesis, 330 
indicating the key role played by the IGF-1R on FSHR-regulated cell proliferation and 331 
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differentiation (22,31). The molecular mechanism(s) proposed for the synergic effects of 332 
FSH and IGF-1 at the receptor level include the ability of activated FSHRs to inhibit 333 
dephosphorylation of the IGF-1R by protein kinase phosphatases, such as PTP-1B and 334 
Src homology 2 domain-containing phosphatase 2 (SHP-2), both expressed in granulosa 335 
cells (118-120). Alternatively, the interaction between molecular chaperones and IGF-1R 336 
may be enhanced, as suggested by the prevention of cyp19 and P450scc expression in 337 
response to FSH by HSP90 (heat-shock protein 90) inhibition (33).  338 
 339 
Another receptor modulating FSH-stimulated granulosa cell proliferation and 340 
differentiation in the developing follicle is the EGFR, which participates in phosphorylation 341 
of ERK1/2 and p38MAPK in granulosa and cumulus cells of preovulatory follicles (121-342 
123). Thus, in addition to EPAC and Rap1 in promoting p38MAPK phosphorylation (see 343 
above), FSH-stimulated induction of EGF-like factors, like AREG, appears as well to play 344 
an important role in the PKA-independent activation of MAPK signaling in developing 345 
granulosa cells (24,124,125). Additional studies have further indicated that besides 346 
promoting activation of the MAPK cascade,  AREG and FSH stimulate Akt and FOXO1a 347 
phosphorylation through activation of members of the Src family of tyrosine kinases or 348 
SFKs (24). As in the case of the IGF-1/IGF-1R pathway described above, it appears that 349 
the AREG/EGFR/RAS and FSH/FSHR signaling pathways converge on common 350 
downstream targets, mainly ERK1/2, p38MAPK and Akt phosphorylation, leading to up- 351 
and downregulation in the expression of different genes that impact on both follicle 352 
maturation and granulosa cell differentiation into granulosa-lutein cells exhibiting 353 
functional and steroidogenic profiles that differ from those exhibited by maturing 354 
granulosa cells (1,123,126-128). The importance of the EGF/EGFR pathway in follicular 355 
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maturation and ovulation is emphasized by studies in mice showing that the absence of 356 
Areg results in subfertility and decreased response to exogenous gonadotropin treatment 357 
(129).   358 
 359 
In addition to cross-talk with the IGF-1R and EGFR, the FSHR interacts with the 360 
structurally-related LHCGR. Although the functional relationship between these two 361 
gonadotropin receptors had been well recognized for a long time, it was only recently that 362 
functional cross-talk and physical interaction between gonadotropin receptors were 363 
reported (26,40,41). Hetero-oligomerization of the FSHR and LHCGR has been 364 
demonstrated using BRET, fluorescence correlation spectroscopy, and more recently, 365 
photoactivatable-localization microscopy (PALM) (<10 nm resolution) (26,130,131). 366 
Biochemical studies in HEK293 cells, showed that when heterodimerized, FSH and 367 
LHCG receptors exhibited cross-inhibitory effects on Gs signaling: heterodimerization of 368 
LHCGR with FSHR led to attenuation of LH-stimulated cAMP production, whereas when 369 
FSHR heterodimerized with LHCGR, FSH-stimulated second messenger production was 370 
mitigated (40). More recently, Jonas and colleagues (26) employed PALM to detect 371 
physical and functional interaction between the FSH and LHCG receptors in human 372 
granulosa-lutein cells. They found that both receptors associate as functionally asymetric 373 
heteromers, and that this association leads to prolonged LH-stimulated Ca2+ signaling via 374 
influx of extracellular calcium in a Gaq/11- and Gbg-dependent manner (26). 375 
Concurrently, these data demonstrate that gonadotropin receptors, when 376 
heterodimerized, may undergo allosteric regulation, with one receptor impacting on cell 377 
signaling triggered by the other as previously suggested (42). Cross-talk between 378 
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gonadotropin receptors may be potentially important for reproductive function, given that 379 
in vivo both receptors coexist in granulosa cells, particularly during the last stages of 380 
follicle development prior to ovulation (1).  381 
 382 
Signal termination and biased agonism 383 
 384 
Signal termination at the FSHR is a tightly regulated multistep process known as 385 
homologous desensitization. First, GRKs rapidly phosphorylate serine/threonine residues 386 
of the FSHR COOH-terminus (5,36,85,93-95). Second, b-arrestins 1 and 2 are recruited 387 
and prevent Gs interaction with the core domain of the FSHR through steric hindrance 388 
(5,54,94,95,132). Third, the amount of intracellular cAMP decreases and the receptor 389 
becomes refractory to further FSH stimulation (13,85,86,133). Following desensitization, 390 
the FSHR is rapidly internalized and predominantly resensitized, with a minor fraction of 391 
the FSHR being degraded (54,85,134). Interestingly, the FSHR was recently reported to 392 
traffic to very early endosomes for its post-endocytic sorting rather than early endosomes 393 
like most GPCRs (135-137) (Fig. 2). In contrast with Gs, which leads to full cAMP 394 
response with less than 5% of FSHR occupancy, more than 90% of FSHR molecules 395 
need to be occupied to achieve maximal b-arrestin recruitment and internalization (54).  396 
 397 
Major advances in GPCR structural biology over the last decade have profoundly 398 
changed the conceptual basis of receptor activation and pharmacological efficacy. In 399 
particular, it is now appreciated that GPCRs adopt multiple inactive and active 400 
conformations that are connected to distinct transduction mechanisms (12,138-147). 401 
Accordingly, it has been shown that a given ligand or receptor mutation can modify the 402 
stabilized conformation of the receptor-ligand complex, as compared to the wild-type 403 
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receptor-reference-ligand complex (Fig. 3). This phenomenon is generally referred to as 404 
pharmacological bias (12,138,141,144). Practically, this conceptual framework delineates 405 
two levels of pharmacological bias. First, ligand bias that are elicited by certain ligands 406 
that stabilize a subset of the receptor conformations, leading to an imbalance between 407 
the signaling pathways activated when compared to the reference agonist. Second, 408 
receptor bias that can occur in the case of mutations [e.g. in the case of FSHR Met512Ile 409 
mutation at the second extracellular loop or Ala189Val mutation at the ECD] (7,148,149) 410 
or of single nucleotide polymorphisms (e.g. the Asn680Ser polymorphism, Fig. 1) 411 
(150,151) at the receptor level, leading to imbalanced or impaired signaling compared to 412 
the wild-type receptor (Fig. 3).  413 
 414 
Different classes of small molecules capable of modulating FSHR have been 415 
identified (152-157), including three negative allosteric modulators (NAMs) (51,52,158). 416 
ADX61623 increased the affinity of FSH binding, yet blocked FSHR-mediated cAMP and 417 
progesterone but not estradiol production in rat primary granulosa cells, whereas in vivo, 418 
it did not affect FSH-induced preovulatory follicle development (51). Two other NAMs, 419 
ADX68692 and ADX68693, with structural similarities to ADX61623, were subsequently 420 
shown to exhibit biased NAM activities on FSHR in rat primary granulosa cells (52,158): 421 
ADX68692 blocked FSHR-promoted cAMP, progesterone and estradiol production 422 
whereas ADX68693 inhibited cAMP and progesterone with the same efficacy as 423 
ADX68692 but did not block estradiol production. Importantly, ADX68692 but not 424 
ADX68693 decreased the number of oocytes recovered in the ampullae (52). A positive 425 
allosteric modulator (PAM), Org 214444-0, has also been described (159); this PAM 426 
exhibited nanomolar FSHR agonistic effects and selectivity over the structurally related 427 
  Ulloa-Aguirre et al, minireview V2 revised 
 20 
LHCGR and TSHR. When co-incubated with FSH, Org 214444-0 increased FSH binding 428 
and cAMP activation. Furthermore, in vivo, Org 214444-0 recapitulated the action of FSH 429 
in a model of fertility in rat. More recently, another series of small molecules acting as 430 
agonist-PAMs were reported (160-162). These thiazolidinone derivatives have been 431 
shown to activate FSHR signaling in CHO cells and to enhance estradiol production in 432 
cultured rat granulosa cells (161). In addition, optimization of substituted benzamides led 433 
to more FSHR-selective molecules (162). Small molecules have also been reported to 434 
behave as competitive antagonists. First, suramin has been shown to inhibit testosterone 435 
production and FSHR signaling (163,164). Another compound displaying similar 436 
antagonistic properties as suramin but with much better specificity for FSHR was later 437 
described (165). With the notable exception of the ADX series, whether these compounds 438 
lead to balanced or biased agonism/antagonism compared to FSH remains unknown and 439 
will need further investigation. 440 
 441 
In the same line, it has long been suggested that naturally occurring FSH 442 
glycoforms may also elicit distinct effects on target cells (166). The common α-subunit 443 
and FSHβ each contain two N-linked oligosaccharides (at positions Asn52 and Asn78 on 444 
FSHα and at Asn7 and Asn24 in FSHβ) that play a pivotal role in the functional properties 445 
of the hormone (167-170). Removal of the carbohydrate residue at position 78 on the α-446 
subunit significantly increases receptor binding affinity of human FSH. Likewise, 447 
carbohydrate at position 52 on the α-subunit was found to play an essential role in signal 448 
transduction since its removal resulted in a significantly decreased potency. A 449 
hypoglycosylated FSH (FSH21/18) was 9- to 26-fold more active than fully-glycosylated 450 
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FSH (tetra-glycosylated FSH24) in binding and functional assays (171,172). Another 451 
human FSH deglycosylated variant, which possesses only α-subunit oligosaccharides, 452 
was significantly more bioactive in vitro than the tetra-glycosylated form of the hormone 453 
(173,174). In contrast, hyperglycosylated FSH enhanced the number of ovulated eggs 454 
and subsequent in vitro embryo development (175). Interestingly, partially deglycosylated 455 
eLH (eLHdg) behaved as a biased agonist at the FSHR, eliciting β-arrestin recruitment to 456 
FSHR as well as ERK and rpS6 phosphorylation in a β-arrestin-dependent and Gs/cAMP-457 
independent manner (50). 458 
 459 
 The effects of FSH21/18 and FSH24 has further been studied in vivo (176). 460 
Administration of these FSH glycoforms to Fshb null female mice induced expression of 461 
several FSHR downstream signaling pathway components, including phosphorylated 462 
forms of CREB, PKA, Akt, p38, and p42/44 ERK, and FSH-regulated genes (e.g. Cy19a, 463 
inha, and inhbb) in a similar manner, albeit with some differences in the kinetics of 464 
response between the two glycoforms. In contrast, when FSH21/18 or FSH24 was 465 
injected to Fshb null males, differential up- and down-regulation in expression of the nine 466 
FSH-responsive genes analyzed (e.g. in cdo1, Clu, Tbx22, Zic3, Car13, Amh and FSHr) 467 
was observed, suggesting biased agonism of the FSH glycoforms at the Sertoli cell level 468 
in vivo (176). Whether the functional selectivity shown by hypo- and fully-glycosylated 469 
FSH is only due to differences in binding affinity or to stability of interaction with the FSHR 470 
(171,177), or actually to induction of distinctly different receptor conformations leading to 471 
selective activation of downstream signaling pathways, still remains to be analyzed in 472 
more detail.  473 
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 474 
Another class of potential ligand bias comes from cases where structural 475 
constraints are conveyed on the hormone by an antibody, leading to the modification of 476 
its pharmacological properties (14). Polyclonal anti-peptide antibodies against ovine 477 
FSHβ subunit led to a significant enhancement of biological activity in vivo in mice (178). 478 
Likewise, the use of a monoclonal antibody against bovine FSH in snell dwarf mice 479 
showed an increase in uterine weight (179). Studies also evaluated the impact of equine 480 
chorionic gonadotropin (eCG)/anti-eCG complexes on gonadotropin bioactivities. They 481 
showed that anti-eCG IgGs were either inhibitory or hyper-stimulatory on LH and FSH 482 
bioactivity (180). Furthermore, Wehbi and colleagues (49) discriminated the nature of 483 
these complexes on FSH signaling and revealed their biased properties. 484 
 485 
Conclusions 486 
 487 
From the above discussion, it is clear that FSH-stimulated intracellular signaling is 488 
mediated through an intricate network whose dynamic properties depends on the stage 489 
of target cell development and cell context, which may in turn be regulated by numerous 490 
factors intrinsic to the cell and by the ligand. These factors include changing ligand pulse 491 
frequency and local concentrations, particular structure (166,172,176,181-183), and 492 
interaction dynamics with the FSHR (177).   493 
   494 
Since the multiple components of the FSHR-regulated signaling network (Fig. 2) 495 
are activated neither with the same amplitude nor at the same time, the temporal and 496 
dynamical aspects that govern the kinetics of the biochemical reactions involved has to 497 
be considered. These complex dynamics can be approached with computational 498 
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modeling using ordinary differential equations, as proposed previously for the FSHR 499 
(78,184). For example, in granulosa cells, FSH-induced cAMP pathway dynamics has 500 
been modelled with careful examination of steady-states and parameter sensibility (184). 501 
Dynamic interactions between cAMP and mTOR pathways, that converge onto p70S6 502 
kinase activation by FSH or insulin was modelled using experimental data from primary 503 
Sertoli cells (48). This model provided clues on p70S6 kinase phosphorylation rates and 504 
was experimentally validated using pharmacologically perturbed conditions. Further 505 
developments of FSHR network modeling will help to fill the gap between detailed 506 
knowledge on molecular interactions and comprehensive understanding of hormonal 507 
dynamics. Functional interactions of the FSHR with several tyrosine kinase receptors 508 
other than the IGF-1R and EGFR described above, may further increase the landscape 509 
complexity. These include the neurotropic factors GDNF (glial cell line-derived 510 
neurotropic factor) (185) and BDNF (brain-derived neurotrophic factor) (186) receptors, 511 
as well as receptors of the TGFβ family members (187), known to potentiate the mitogenic 512 
action of FSH in Sertoli cells and/or granulosa cells. These aspects will require further 513 
investigation. 514 
 515 
Since the first pioneering evidence that the gonads exhibit binding sites specific for the 516 
FSHR and respond to FSH by increasing intracellular cAMP levels (16,188-191), 517 
significant advances in our understanding of the structure and function of the FSH/FSHR 518 
system has been achieved. Nonetheless, there are still important issues that remain to 519 
be elucidated and that will require the application of new experimental paradigms, “omic” 520 
technologies (genomic, transcriptomic, and proteomic techniques), and systems biology 521 
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tools to facilitate this challenging task. These issues include, for example, a more detailed 522 
elucidation of the mechanisms underlying differential gene expression and protein 523 
phosphorylation during granulosa cell differentiation and follicle maturation under the 524 
influence of FSH variants, FSH analog compounds, and FSHR allosteric modulators, 525 
which may convey important therapeutic benefits to the clinical arena. To this end, in vitro 526 
experimental models such as intact follicle culture or three-dimensional bioprosthetic 527 
ovary models that may better reproduce the physiological environment of the developing 528 
follicle may be applied; these systems might allow to explore more deeply the signaling 529 
pathways and gene expression profile induced by FSH both in target cells in their in-situ 530 
arrangements and within different granulosa cell compartments throughout follicle 531 
maturation (192-194). As noted above, further studies are also needed not only to validate 532 
the existence of extragonadally-expressed FSHRs but also to dissect in more detail their 533 
corresponding signaling networks and pathways as well as gene expression profiles, 534 
which might eventually allow to assign them physiological roles according to their 535 
particular location. Integration of large-scale information obtained from these techniques 536 
will undoubtedly facilitate the building up of more integrative signaling framework models 537 
that may be applied to simulate in silico the biological consequences of intermittent FSH 538 
stimuli on its target cell in multiple-way combinations. Beyond any doubt, past and present 539 
studies may just represent the prologue to what remains to be unveiled.   540 
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Figure legends  1210 
 1211 
Figure 1. Schematic representation of the human FSHR with the cytoplasmic face 1212 
of the TMD and the C-tail magnified and the extracellular domain removed at 1213 
residue 352. The schematics show the locations of sequences, motifs, and residues 1214 
involved in internal agonist (FNPCEDIMGY sequence shaded in dark red); G protein 1215 
coupling and receptor activation (ERW motif, NPXXY motif, and BXXBB motif reversed 1216 
at the IL3); interaction with APPL1 (residues 393, 394, and 399 at the IL1), 14-3-3t (IL2), 1217 
ubiquitin, and PKC2 binding (IL3); receptor trafficking [F(X6)LL and BXXBB motif reversed 1218 
at the NH2-terminal end of the C-tail]; phosphorylation of the receptor by GRK (putative 1219 
class B cluster); palmitoylation (Cys644, 646, and 672) and postendocytic fate (residues 1220 
684 and 688-690). Also indicated is the location of the most common FSHR 1221 
polymorphism (Asn680, light yellow circle) as well as of inactivating (red circles) and 1222 
activating (green squares) FSHR mutations involving the TMD and IL3, which may impact 1223 
receptor trafficking and/or activation and signaling [reviewed in refs. (4-6)]; the mutation 1224 
at position M512 (magenta circle in the EL2), has been associated with biased signaling 1225 
(7). Numbering of the amino acid residues includes the leader sequence. EL, extracellular 1226 
loop; IL, intracellular loop; TMD, transmembrane domain, C-tail, intracellular COOH-1227 
terminus. 1228 
 1229 
Figure 2. A simplified overview of the FSHR signaling network. The color code, 1230 
depending on the arbitrarily main effector, is as follows: green for PI3K-dependent 1231 
signaling, orange for cAMP-dependent signaling, red for β-arrestin-dependent signaling, 1232 
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regardless that some signaling effectors (e.g. ERK or p70S6K) are commonly activated 1233 
by these three pathways. Mechanistic details have been omitted for the sake of clarity. Of 1234 
note, the phosphorylation state of the FSHR conveyed by GIPC is not known. This 1235 
network has been established by using the Cell Designer algorithm (45) and the meaning 1236 
of symbols is shown in the rectangle at the bottom. AC, adenylyl cyclase; AMPK, AMP-1237 
activated protein kinase; DAG, diacylglycerol; DUSP, dual specificity phosphatase 6; 1238 
eIF4, eukaryotic translation initiation factor 4; GIPC, Gai-interacting protein C terminus; 1239 
PARK, E3 ubiquitin protein ligase Parkin; PINK, PTEN-induced putative kinase; PIP3, 1240 
phosphatidylinositol (3,4,5) triphosphate; VEE, very early endosome. 1241 
 1242 
Figure 3. Principle of biased agonism triggered at the FSHR by allosteric ligands. 1243 
(a) Upon agonist binding, FSHR (yellow) recruits Gs (red), leading to cAMP production 1244 
and ERK phosphorylation. Agonist binding also triggers b-arrestins (light green) 1245 
recruitment and cAMP-independent ERK phosphorylation. (b) Balanced allosteric ligand 1246 
(inverted green triangle) can activate FSHR in the absence of FSH and recruits similar 1247 
proportion of Gs and b-arrestin as FSH. (c) Gs-biased allosteric modulator (inverted 1248 
orange triangle) preferentially induces Gs-dependent signaling. (d) b-arrestin-biased 1249 
allosteric modulator (inverted blue triangle) preferentially elicits b-arrestin-dependent 1250 
signaling. Other possible combinations are not represented. FSHR ECD: Follicle-1251 
stimulating hormone receptor extracellular domain. 1252 
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